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Abstract 
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) has caused worldwide panic 
during 2020.  To date SARS-CoV-2, the virus causing COVID-19, has caused 1 million deaths 
and infected over 35 million people in under 10 months.  On the other hand, influenza A virus 
(IAV) has been responsible for several epidemics and millions of deaths during the last 100 
years.  Our study joins the race to identify novel COVID-19 treatments by investigating the 
antiviral capabilities and clinical potential of a series of antimicrobial peptides and peptoids 
against these two important respiratory viruses.  The project aimed to identify potential 
candidates within a panel of peptides (n=4) and peptoids (n=14) kindly provided by Dr. Daniel 
Pletzer (University of Otago, New Zealand) and A/Prof Annelise Barron (Stanford University, 
USA), respectively.  Standard drug discovery strategies were employed to determine the ability 
of the peptides/peptoids to inhibit viral replication (EC50 values), while causing negligible 
cytotoxicity (CC50 values) in different cell lines.  We uncovered 8 peptides/peptoids which 
showed antiviral activity against IAV (EC50 values ranging from 49 µg/ml  to 5.7 ug/ml), as 
well as 12 antimicrobial peptides/peptoids able to inhibit the replication of SARS-CoV-2 (EC50 
values range, 41 µg/ml to 3.2 ug/ml). In summary, promising selectivity index (SI) values 
warrant continued characterization of the antiviral activity of the novel antimicrobial 
peptides/peptoids, including but not limited to (i) verifying their specificity by testing other 
influenza and coronavirus strains and (ii) in vitro selection of viruses with reduced 
susceptibility to these peptides/peptoids.  Our results add to the growing evidence that some 
antimicrobial peptides and peptoids are also capable of inhibiting viral replication.  The need 
for additional SARS-CoV-2 and IAV treatments is urgent and studies such as this one 
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1. Introduction 
1.1 Respiratory viruses 
1.1.1 Overview 
Viruses are microscopic infectious particles which must inhabit living cells, in order to access 
their cellular machinery required for replication.  There are viruses adapted for every living 
organism from humans and animals to plants and microorganisms.  Viruses have become 
highly specialized to attach to and enter living cells; processes achieved through viral protein 
and host receptor binding (2, 3).  
 
Respiratory viruses specifically infect the cells within the respiratory system of the host 
organism.  Although often asymptomatic or restricted to minor symptoms such as a sore throat, 
running nose and cough, in instances where the host is immunocompromised or the virus itself 
is especially pathogenic, severe inflammation can result (4).  The typical symptoms of a 
respiratory virus infection are usually the result of an inflammatory immune response launched 
by a host once it has detected a foreign body (5).  Such inflammation can occur in the lungs, 
resulting in pneumonia; in the brain resulting in encephalitis; and the heart, resulting in 
myocarditis (4, 6-8).   
 
The most common cause of respiratory infections are viruses from families such as 
Rhinoviridae, Orthomyxoviridae, Paramyxoviridae, Pneumonviridae, Adenoviridae, and 
Coronaviridae (9).  Arguably the most pressing and dangerous respiratory viruses belong to 
the Orthomyxoviridae and Coronaviridae families (9, 10).  Members of the Orthomyxoviridae 
family, such as influenza A (IAV) and B (IBV) viruses, are a persistent public health burden 
   2 
through seasonal epidemics (10).  IAV and IBV are constantly adapting viruses, which undergo 
regular (10-3–10-4 per year per site) mutations under positive selection pressure, allowing them 
to evade immunity year after year (11, 12).  Both genera have the ability to undergo antigenic 
drift where the gradual collection of mutations on surface proteins leads to lowered binding 
between the virus and host immune response (13).  Additionally, IAV also has the ability to 
undergo antigenic shift where the hemagglutinin or neuraminidase surface proteins are 
replaced by novel subtypes (13).  This often results in pandemic scale outbreaks due to the lack 
of human immunity.  So, although they are extensively studied, IAV and IBV require new 
therapies and treatments at an accelerating rate (14-16).   
 
Emerging viruses such as Influenza D virus (IDV), Severe Acute Respiratory Syndrome 
Coronavirus (SARS-CoV), Middle-East Respiratory Syndrome Virus Coronavirus (MERS-
CoV) or the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) offer 
different but equally challenging obstacles.  As humans have no natural immunity to these 
emerging viruses, they often result in unpredictable and severe outbreaks or even pandemics, 
as is currently evident (15-17).  In order to develop treatments to these viruses it is essential 
that we understand not only their biology but also their pathogenicity and virulence (16, 18) 
 
1.1.2 Influenza viruses  
Influenza viruses are enveloped single-stranded RNA viruses from the Orthomyxoviridae 
family (19).  They are categorised into the genera Alphainfluenzavirus (A), Betainfluenzavirus 
(B), Gammainfluenzavirus (C), Deltainfluenzavirus (D).  Three of these viruses are known to 
infect humans; IAV, IBV and Influenza C Virus (ICV).  While the most recently discovered 
IDV has not reported human infection, there is serologic evidence of IDV in humans and it is 
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widely believed that it is only a matter of time before the first symptomatic human case is 
documented (17, 20-22).   
 
Influenza viruses account for ~30% of human respiratory infections, however they often cause 
only minor symptoms such as muscle aches, fatigue, cough and running nose(23).  
Nevertheless,  infections can be severe, specifically in those who are immunocompromised, 
resulting in influenza related deaths (23, 24).  Due to its varying severity and high endemic 
global prevalence, it is difficult to accurately estimate the number of infections of influenza 
viruses per year.  However, the most recent data estimates that there are 290,000 to 645,000 
annual influenza related deaths (25).   
 
IAV, is an 8 gene segment virus discovered in 1931 (26).  These segments encode RNA 
polymerase subunits, matrix proteins, nucleoproteins and non-structural proteins as well as the 
envelope proteins encoded by the haemagglutinin (HA) and neuraminidase (NA) genes 
(19).  IAV is classified into subtypes based upon which type of HA and NA surface protein the 
virus carries (27).  These envelope proteins are involved in the pathogenicity of IAV through 
attachment to host and release of viral progeny.  With the known 18 variations of HA gene and 
11 variations of the NA gene, there are a total of 198 subtypes possible (28).  Each variation of 
these proteins is given a number, with the subtypes being labelled accordingly i.e., H1N1.  Most 
current research agrees that the host range for IAV is extensive with different subtypes 
preferentially inhabiting different organism (27, 29, 30).  For example, subtypes most 
commonly infecting humans include HA1, HA2, HA3, NA1, and NA2.  In general, humans, 
pigs, and birds seem to harbour the largest number of subtypes (26).  
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Understanding the life cycle of IAV is of utmost importance to the discovery of potential 
preventatives and treatments, as it gives insight to the type of antiviral that may be affective 
(31-33).  The influenza lifecycle is shown in Figure 1, starting with IAV attachment to the host 
cell via the HA and host receptor sialic acid interaction (34-36).  This interaction stimulates 
the endocytosis of the virus into the host cell and then fusion with a lysosome.  The acidic 
interior of the lysosome triggers the virus to channel protons into its nucleocapsid, breaking 
down the connections between the matrix proteins and proteins surrounding the RNA genome.  
In addition to these internal changes, the acidity also forces a conformational change of the HA 
and sialic acid interaction, allowing the HA to attach to the lysosome membrane and stimulate 
membrane fusion.  This is also known as the uncoating process and allows the viral proteins to 
enter the cell cytoplasm.  
 
Following this, the ribonucleoproteins enter the nucleus through the nucleic pores.  The 
negative-sense RNA segments are copied into positive-sense segments via the viral RNA 
polymerase.  During this process a polyA tail is added as well as a 5’ cap through the process 
of cap snatching.  RNA then either leave the nucleus to be translated into proteins via the host 
cell ribosomes or remains in the nucleus to be translated back to negative-sense genome 
segments for the progeny virion.  Surface proteins translated in the endoplasmic reticulum and 
modified by the golgi apparatus are exported as a vesicle to the cell membrane where they 
encapsulate the other viral proteins to form progeny viruses as they bud from the cell 
membrane. NA surface protein then cleaves the connection between the virion progeny and the 
host cell, allowing its release (34). 
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IAV is the only genus of influenza virus which is known to cause pandemics.  Subtype H1N1 
was responsible for both the 1918 and 2009 flu pandemic killing at least 50 million people (26, 
37, 38).  Similarly, the H2N2 and H3N2 subtypes were responsible for the 1957 and 1968 flu 
pandemics respectively killing somewhere between 2 and 8 million people (37, 39, 40).  In 
addition, H5N1 also known as high pathogenic avian influenza (HPAI) is not as common in 
humans but in reference to its name, is highly pathogenic.  HPAI has had a 60% fatality rate 
since 2003 and regularly infects populations of poultry and waterfowl (41, 42).  The pandemic 
and epidemic potential of IAV has been demonstrated repeatedly over the past 100 years, 
indicative of the increasing need for better preventative and therapeutic measures.  
Figure 1 An overview of the Influenza A Virus (IAV) life cycle. 
The lifecycle of IAV follows 9 steps. (1) Viral haemaglutinnin (HA) binds host cell sialic acid and (2) initiates 
fusion and endocytosis into the cell. (3) Once inside the cell the viral vesicle is fused with a lysosome creating an 
acidic environment which stimulates conformational changes in HA binding, allowing escape from the vesicle.  
Viral RNA enters the cell nucleus where it initiates it replication process. (5) Proteins and (6) ribonucleic protein 
complexes (RNP) are synthesized by the host ribosomes before (7) assembling at the host cell membrane with the 
surface proteins. (8) The cell membrane undergoes budding to (9) release the viral progeny with the help of 
cleavage of the sialic acid receptors by neuraminidase. Image adapted from (1) using Biorender.com 
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IBV, similar to IAV, has an 8-segment genome, but was discovered a decade later in 1940 
(26).  In contrast to IAV, it has a much smaller host range mainly infecting humans and pigs 
(19, 26). Unlike the multiple subtypes of IAV, IBV is also only categorised into two lineages: 
B/Yamata/16/88 and B/Victoria/2/87 (43). 
 
IAV and IBV both contribute to the seasonal influenza epidemics seen across the world (25).  
But despite continued IAV research, the rates of infection were the highest in the USA 2017-
18 influenza season since 2009, with the CDC estimating around 35.5 million infections and 
34,200 related deaths (44).  Indicating the clear need for new effective treatments.  
 
1.1.3 Coronaviruses 
Coronaviruses are enveloped RNA viruses belonging to the Coronaviridae family, which tend 
to cause respiratory illnesses in their hosts (45).  Around 15% of common colds are caused by 
one of the four endemic coronaviruses infecting humans (45) two of which are 
alphacoronaviruses (Human coronavirus 229E and Human coronavirus NL63), while the other 
two are betacoronaviruses (Human coronavirus OC43 and Human coronavirus HKU1) (45, 
46).   
 
Due to their abundance in animals, coronaviruses have been acknowledged as having serious 
endemic or pandemic potential for many decades (47, 48).  The first documented coronavirus 
outbreak in humans was Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) in 
2003 (15).  SARS-CoV resulted in around 8000 confirmed cases and 774 deaths putting its 
case fatality rate at ~10%.   Leading on from this, in 2012 another coronavirus outbreak 
occurred, this time in the Middle East resulting in the official name of the virus Middle East 
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Respiratory Syndrome Virus, MERS-CoV.  To date MERS-CoV has only infected 2494 
people, and resulted in 858 deaths, putting its case fatality rate at around 37% (15).  
 
The most recent and significant coronavirus outbreak is the ongoing Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2).  As of October 11th 2020, 37 million people have 
been infected with the virus and 1 million have died since December 2019 (20).  Current data 
for SARS-CoV-2 shows a fluctuating case fatality rate of somewhere between 0.1%-16.6% 
depending on age and geographical distribution, a much lower rate of death when compared to 
the more pathogenic SARS-CoV and MERS-CoV(49-52).  However, what sets this novel 
coronavirus apart from MERS-CoV and SARS-CoV is its human transmissibility (45).  Current 
data estimates the R0 value of SARS-CoV-2 to be ~2.5, making it a highly infectious virus (53, 
54).  These coronavirus outbreaks are an informative way to see what is required for a virus to 
be a global health burden.  The combination of a 5-11 day incubation period and extremely 
high transmissibility in humans (as seen with SARS-CoV-2), makes it extremely difficult to 









   8 
 
As with IAV, it is essential to understand the lifecycle of SARS-CoV-2 in order to develop 
targeted and effective preventatives and treatments.  As seen in Figure 2, SARS-CoV-2 enters 
the host cell through binding of the S surface protein to the ACE2 host receptor(55).  This 
initiates the process of viral entry where ACE2 is cleaved by a host protease and S proteins 
undergo conformational changes allowing viral entry.  SARS-CoV-2 genomic material is 
released into the cytoplasm as mRNA and is translated by host RNA polymerase into 
polyproteins pp1a and pp1ab before being cleaved into non-structural proteins (nsps).  These 
non-structural proteins will go on to form the replicase-transcriptase complex which mediates 
Figure 2: An overview of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Life CycleThe 
lifecycle of SARS-CoV-2 begins with the SARS-CoV-2 Spike (S) surface protein (1) binding host cell ACE2. This 
initiates viral entry and the viral genome is (2) released into the host cytoplasm before being (3) translated into 
polyprotein 1a and 1b. These polyproteins are cleaved producing complexes including RNA polymerase. RNA 
is replicated as both - (4) and + (5) sense before translation (6) of structural proteins occurs in the host 
endoplasmic reticulum. Surface proteins and nucleocapsid combine (7) enveloped inside of a vesicle (8) forming 
a mature virion, before undergoing (9) exocytosis. Image adapted from Biorender.com 
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the synthesis of viral RNA and includes complexes such as the RNA-dependent RNA 
polymerase (RdRp)(56).  Here a genomic template of SARS-CoV-2 is able to be created, 
providing replication of positive-sense genomic mRNA.  The subgenomic proteins are 
translated into structural proteins that undergo post-translational modification in the host 
endoplasmic reticulum and golgi apparatus.  Genomic mRNA and the subgenomic proteins 
converge at the endoplasmic reticulum–Golgi intermediate compartment (ERGIC) before 
being exported out of the host cell via exocytosis.    
 
1.2 Combating respiratory Viruses 
1.2.1  Prevention 
Preventing infection with IAV and SARS-CoV-2 is the first step in managing the diseases they 
cause and the associated health burden they place on communities.  The most common system 
healthcare workers and researchers use to understand continued infection in human populations 
is called the chain of infection (57).  In order to control a virus you must break one of the links 
in the chain of infection, which are: the reservoir, the portal of exit from the reservoir, the mode 
of transmission, the portal of entry into the host, the susceptible host, and the infectious agent.  
Many prevention methods will break multiple links in this chain.  For example, regularly 
sanitising surfaces as well as practicing good personal hygiene (washing and sanitising hands, 
covering nose and mouth when coughing or sneezing), will break the chain at almost all the 
links.  This is particularly important for IAV and SARS-CoV-2 where infectious droplets can 
survive on surfaces for varying amounts of time and may in the case of IAV become 
aerosolised, remaining suspended in the air for an extended period of time(58, 59).  
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In addition to the aforementioned methods, isolation of the infected person will help prevent 
these infectious droplets from coming in contact with more hosts.   Isolation of infected people 
becomes more important when immunocompromised individuals are involved as they carry a 
higher risk of infection and severe complications, so extra precautions should be taken to 
ensure the safety of vulnerable people (57, 60, 61).  Extra sanitation and social distancing as 
well as making sure their health condition is managed as well as possible (e.g. correct 
medications and control in asthma and diabetes) will limit their risks  (57, 62).  In addition, 
wearing a mask in enclosed areas to prevent human transmission has shown to be particularly 
effective in the ongoing SARS-CoV-2 pandemic(63, 64).   
 
Another important aspect to note is the animal reservoirs of viruses.  Both IAV and SARS-
CoV-2 are adapted to survive in zoonotic hosts as well as humans.  Because of this,  proper 
care of animals and preparation of meats which may transmit viruses to humans is essential in 
preventing viral outbreaks.  In the case of IAV and SARS-CoV-2, both viruses are relatively 
vulnerable outside of the host so preventative methods at any link in the chain of infection are 
highly effective (65-68).  
 
1.2.2  Vaccines 
Although prevention techniques surrounding the chain of infection can be very effective, as 
seen with the anti-SARS-CoV-2 strategies in New Zealand, the best way to prevent a virus 
from spreading is to vaccinate a large portion of the population (69).  This prevents the virus 
from infecting whole communities through establishing herd immunity (70-72).  Vaccines 
work through exposing the immune system to a safe amount of viral antigen, usually through 
the injection of inactivated or attenuated virus or viral components (73, 74).  The body launches 
an immune response against the foreign components of the vaccine. Following this immediate 
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response memory cells are formed, resulting in long term, adaptive immunity against the 
antigen (75).  Triggering an adaptive immune response means that when the immune system 
encounters the pathogenic virus, it can respond quickly with specific antibodies and prevent 
illness (70, 73).  
 
The four main types of vaccines developed are: (i) live attenuated, (ii) inactivated, (iii) toxoid, 
and (iv) subunit (i.e., recombinant, polysaccharide, and conjugate), each of which have 
advantages and disadvantages (70, 76).  Live attenuated vaccines for example, contain a live, 
but weakened pathogen capable of replicating within the host.  This emulates a real life 
infection, producing the best and most sustained immune response, however, it carries the risk 
of the pathogen reverting to the wild type virus and causing disease, especially within 
immunocompromised people (76, 77).  In contrast, inactivated vaccines do not carry the risk 
of causing disease but produce a less sustained and robust immune response due to its inability 
to replicate within cells (78).  Because of this, inactivated vaccines often require adjuvants to 
improve performance but these carry their own risks of increasing side effects at the vaccine 
site (76, 78).   
 
The IAV vaccine is a great example of a vaccine which can either be inactivated or live 
attenuated and provide effective herd immunity every year with minor adjustments(74).  The 
influenza vaccines are created annually in anticipation of which strains of influenza are likely 
to be circulating.  Most annual vaccines are quadrivalent meaning they protect against four 
different strains across IAV and IBV.  They always contain the two lineages of IBV, 
B/Yamata/16/88 and B/Victoria/2/87, combined with the two most likely subtypes of 
IAV.  Recently, these vaccines have protected against infection with H1N1 and H3N2 (79, 80).  
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When the correct vaccines are used for each specific virus, they are the current most effective 
and efficient way to protect individuals and populations from becoming infected (73, 81). 
 
1.2.3  Antivirals 
While the above tactics work to prevent infection, antivirals aim to eliminate the virus once an 
individual is infected.  This strategy is used to prevent an individual becoming increasingly ill, 
while also lowering the health burden and fatality rate of the disease caused by the 
virus.  Broadly speaking, antivirals are any compound which can be used to lower the viral 
load within an infected individual, usually through the inhibition of one or more steps in the 
viral life cycle as opposed to being virucidal (82).   Although different in every virus, the life 
cycle usually follows the same pattern of attachment to host cell, penetration through cell 
membrane, release of viral genome from endosome, replication of viral genome, synthesis of 
viral proteins, assembly of the virion, and virion release from cell (35).  An effective antiviral 
will intervene at one or more of these stages to prevent it from occurring, e.g., preventing the 
cleavage of the virus particle from the cell as is the case of IAV neuraminidase inhibitors 
(83).  Unfortunately, as with antibacterial resistance, antiviral resistance is on the rise (84, 
85).  There is a constant arms race between modern medicines implemented to defeat viruses, 
and viruses adapting to overcome them.  Antivirals are the last line of defence against our viral 
enemies and their continued discovery and development is vital for our species.  In this review, 
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1.3  Antiviral Strategies  
1.3.1  Drug discovery  
 
 
The entire process of discovering an antiviral drug can take between 10 to 15 years to ensure 
safety and efficacy, much like the time period of vaccine development (86).  As seen in Figure 
3, this process may begin with thousands of potential antiviral drugs which are narrowed down 
to produce a couple of clinically promising antiviral drug options.  Because of this, it is 
imperative that the drug discovery pathway for emerging viruses is started as soon as possible.  
The stages of drug development are: (i) early drug discovery, (ii) preclinical research, (iii) 
investigational new drug application, (iv) clinical research and (v) regulatory review approval 
and post-marketing safety surveillance (87, 88). 
Figure 3: The stages involved in the drug discovery/development pathway The drug development process begins 
at the basic research level with requires screening of large numbers of compounds.  These compounds, of which 
there can be thousands, are screened for potential beneficial characteristics.  Preclinical research is undertaken 
on a smaller portion of these compounds which show potential for drug development.  Clinical research takes 
only a couple of the candidates which show the characteristics of interests, and tests them in vivo.  The objective 
of this process is to find a drug which can be approved for clinical use. Adapted from Exploring the Drug 
Development Process. Drug Discovery from Technology Networks https://www.technologynetworks.com/drug-
discovery/articles/exploring-the-drug-development-process-331894. 
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The first step in the drug discovery pathway is to identify potential drug targets on the virus of 
interest and validate their ability to be altered by a drug (87, 88).  Properties which make for 
good drug targets include its ability to be assessed through assay’s for the purpose of drug 
discovery, such as through high-throughput screening (87), and presenting a promising toxicity 
profile, meaning the adverse effects of applying the drug to this target are predictable and 
manageable.  Once a potential target has been identified and verified for its pharmaceutical 
development, the search for drugs can begin.  There are many options for antiviral drug 
discovery including high-throughput screening, structure based design, phenotypic and virtual 
screening (87-89). Following this, the toxicity of a drug needs to be assessed through in vivo, 
in vitro, or in silico models, which have the advantages of emulating the human model, cost-
effectiveness, and being quick respectively (90, 91).  Once several, non-toxic “hits” (drugs 
which interacts with the target) have been found, they undergo more intensive screening known 
as hit-to-lead.  This is where the most promising hits are optimised to increase their ability to 
work as antivirals, such as artificially increasing their affinity to the target (89, 92).  The hit-
to-lead step is also where off target drug interactions which could lead to adverse effects are 
considered and modified.  After this exhaustive process the final stage of early drug discovery 
is the candidate selection.  Here researchers choose the most promising drug candidate which 
they will take forward into preclinical research.  For a drug to be considered a suitable candidate 
it needs to satisfy the biomechanical aspects such as bioavailability and target specificity, as 
well as the economic aspects such as manufacturability and cost-effectiveness (87, 88).  At this 
point in the research the candidate must apply for the ability to move onto animal and clinical 
trials and will be categorised based on its use and profile (87).  In the United States, this is 
known as the “Investigational New Drug Application” and will determine the type of research 
which is allowed to take place as well as the speed at which the process will take (93, 94).  In 
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an emergency situation such as a pandemic or where the drug may be the first treatment for a 
specific illness, the application process may be shortened (87, 95, 96).  
 
The clinical research stage of drug development begins the inclusion of human participants to 
assess the safety and efficacy of the potential drug (88).  Phase I clinical trials is kept to a small 
number of participants (<100) and lasts only a few months.  The purpose of this stage is to 
assess the safety of the drug in a human model, as well as to determine the best way to 
administer the drug (88, 97).  Phase II clinical trials consists of a larger group of participants 
(a few thousand) and may last a few months to a couple of years.  This stage is for testing the 
safety and efficacy of a drug on a larger population for a longer periods of time, with the hopes 
of optimising the method of administration for the next phase.  Phase III clinical trials is 
completed with thousands of participants who are infected with the virus to ensure its efficacy 
across a large group of individuals (88).  This study will last for multiple year with the purpose 
of uncovering any long term or rare adverse side effects which may have been missed in the 
phase I and II clinical trials. 
 
Once a drug has undergone clinical trials, there is still a long way to go before it is generally 
accessible.  The next step is obtaining a series of applications depending on the requirements 
of the country the antiviral is being developed in e.g., New Drug Application and Biologics 
license Application (US) (98) or Marketing Authorisation Application (Europe) (99).  The 
purpose of these applications is to ensure that the drug being put forward is safe, effective, and 
practical for its use.  Once approvals are obtained manufacturing and the normal processes for 
product launching is required, which can take a considerable amount of time and resources 
(100).  
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Finally, the finished antiviral is accessible to patients but it is still closely assessed through 
post-marketing safety surveillance in case of any previously unseen safety issues or adverse 
effects (88, 101).  Post-marketing safety surveillance relies on the surveillance of the antiviral 
on the market however, at the same time, phase IV clinical trials may be carried out.  These 
trials are run after the antiviral has been approved but aims to uncover any long term issues 
that may arise when given to a wider group of people.  
 
It is evident that the long process for producing antiviral drugs is required to ensure the safety 
and efficacy of the drug.  When dealing with IAV and SARS-CoV-2 however, which cause so 
many cases, this process may result in the treatments coming too late.  Because of this, using 
quick and effective methods such as high-throughput screening (87), and adapting already 
known antimicrobials (102) (89, 103) as will be undertaken in my later research, will help 
accelerate the beginning stages of antiviral drug discovery. 
 
1.3.2  Anti-Influenza A Virus Agents 
For influenza A virus we currently rely on preventing infection with an annual vaccine as well 
as the use of antivirals to help treat patients with more severe symptoms.  Most countries 
develop an annual influenza vaccine before the beginning of flu season.  Although this is the 
most protective system we have to date, it will only protect against the strains which you 
inoculate with.  This, in conjunction with lowered vaccine effectiveness seen in recent studied 
is where the need for antiviral drugs arise (74, 104-106). 
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As seen in Figure 4, antivirals have been developed for almost every stage in the IAV life cycle 
and many are in clinical use for severe cases such as those requiring hospitalisation.  One of 
the most common anti-influenza A agents are neuraminidase inhibitors such as: oseltamivir, 
peramivir, zanamivir, and laninamivir(107).  These agents act to prevent the viral surface 
protein NA from cleaving the virion from the host cell.  By doing this, viral cell to cell spread 
is reduced, resulting a lessened viral load.  DAS181 seen at viral attachment on Figure 4, works 
by removing sialic acids from the host cells, reducing the ability of viral attachment (108).  
Adamantanes work through blocking the M2 ion channel of the virus which uninhibited allows 
Figure 4. An Example of Anti-Influenza Agents which Inhibit Different Stages of the Viral Life Cycle.  Image 
shows the life cycle of IAV with note of drugs which are known to inhibit viral replication at different stages.  
DAS 181 inhibits binding of IAV to host cell.  Adamantanes prevent the release of viral genome from the lysosome 
through inhibiting M2 ion channels.  Favipiravir and Ribarivin prevent the synthesis of viral RNA polymerase.  
Nitazoxanide prevents the assembly of the viral components through inhibiting intracellular transport.  
Neuraminidase inhibitors prevent the release of IAV from the host cell through preventing the cleavage of the 
haemaglutinning and sialic acid interaction. Adapted with Biorender.com from Li, T., Chan, M., & Lee, N. 
(2015). Clinical Implications of Antiviral Resistance in Influenza. Viruses, 7(9), 4929-4944. 
https://doi.org/10.3390/v7092850. 
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the influx of protons to the virus filled lysosome (109).  This influx allows conformational 
changes in the HA receptor complex which allows the virus to break free from the lysosome 
into the host cytoplasm.  By preventing this proton influx, IAV is unable to escape the lysosome 
and begin replication.  Once viral RNA has entered the nucleus, antivirals such as Ribavirin 
and Favipiravir can selectively inhibit viral RNA-dependent RNA polymerase (110, 111).  
After the replication of viral RNA in the nucleus, antivirals such as Nitazoxanide are thought 
to inhibit viral replication through the interruption of intracellular trafficking, preventing the 
assembly of the viral progeny (112, 113).  An additional antiviral not shown on figure 4, 
Arbidol, inhibits fusion between the virus and host through binding at the virus active site and 
causing conformational change (114, 115).  
 
One of the main problems facing all of microbiology is drug resistance and it is no different 
when it comes to IAV.  The M2 ion inhibitors such as adamantanes for instance, used to be 
common treatments for IAV but are no longer in use due to the development of resistance IAV 
strains (116-118).  Neuraminidase inhibitor resistance has also been recently noted (119-121). 
 
1.3.3  Anti-SARS-CoV-2 Agents 
Although human coronaviruses have been circulating for hundreds if not, thousands of years, 
outbreaks with novel and more pathogenic coronaviruses such as SARS-CoV and MERS-CoV 
were short lived and limited to a small number of infected people (<8000)(15).  Because of 
this, vaccines against coronaviruses have never been fully developed.  However, the newly 
emerged SARS-CoV-2 poses a long lasting and significant threat to people across the 
globe.  Therefore, the discovery of a vaccine against SARS-CoV-2 as well as antivirals to treat 
infected people is imperative. 
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The SARS-CoV and MERS-CoV outbreaks triggered a huge amount of research into a 
coronavirus vaccine, however, as their numbers of cases started to drop off, so too did the 
search for a vaccine.  Regardless, the research into SARS-CoV and MERS-CoV can be 
somewhat applied to SARS-CoV-2 due to their similarities, and so we have a head start on the 
vaccine development process.  As of October 16th, there are 23 vaccine candidates in Phase II-
II clinical trials with one of the frontrunners being the ChAdOxl nCoV-19 vaccine which has 
entered Phase III clinical trials(122) (123, 124).  
 
While potential antivirals for SARS-CoV-2 are growing by the hour, we have not yet developed 
a specific approved treatment (125).  Remdesivir, which works through blocking the viral 
polymerase resulting in a lowered RNA production has shown enough compelling evidence to 
be approved for emergency use in some countries (126, 127).  In order to speed up the 
development process researchers have studied established anti-influenza drugs such as:  
umifenovir, favipiravir, baloxavir, laninamivir, oseltamivir, peramivir, and zanamivir have 
been assessed for anti-SARS-CoV-2 potential (127).  Umifenovir was the most promising of 
these showing significant reduction in SARS-CoV-2 replication through blocking viral entry 
and was put through to clinical trials (116).  Unfortunately, it has not shown any significant 
results in human trials (128, 129).  Favipiravir, an anti-influenza drug also known to inhibit a 
large variety of viruses such as bunyavirus and flavivirus, has been investigated for it anti-
SARS-CoV-2 activity (130).  While, it was found to inhibit SARS-CoV-2 replication, it 
required a much higher concentration to achieve this than Remdesivir (131).  In spite of the 
accelerated research, as of October 2020, there are no current approved treatments specifically 
for SARS-CoV-2 (125).  
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1.3.4.  Peptides/Peptoids as antivirals agents 
Antiviral peptides are small amino acid chains which act to inhibit viruses at various stages in 
their lifecycle (132).  Antiviral peptoids perform the same task but their structure is slightly 
different with their side chains attached via a nitrogen atom to the peptide backbone as opposed 
to a carbon atom as is seen in peptides (133).  Peptides and peptoids are a promising strategy 
for antivirals as large quantities can be assessed for antiviral properties through high-
throughput sequencing or designed for a specific purpose (134, 135).  
 
Research utilising peptides and peptoids for anti-influenza drugs has been underway for 
multiple years.  Peptides have been studied for their antiviral effects against IAV such as 
peptide-mediated targeting of  the IAV polymerase (PB11-25), use of conserved HA as 
candidates for IAV vaccination (H1 and H2), as well as antiviral peptides which could inhibit 
IAV replication at the fusion stage (peptide P7) (136-138).  Additionally, the pressure of the 
current pandemic has allowed research into the anti-SARS-CoV-2 abilities of peptides and 
peptoids to flow at an accelerated rate.  Many researchers are focussing on designing antiviral 
peptides and peptoids which target either the SARS-CoV-2 spike protein or the host 
angiotensin-converting enzyme 2 (ACE2), the components required for SARS-CoV-2 entry 
into host cells (134, 139-142).  Some examples of this include peptides EK1, HR1, HR2 and 
nelfinavir mesylate, all fusion inhibitors (141, 143-145)  Although the list of peptides and 
peptoids with antiviral potential looks promising, as of September 2020 no antiviral peptides 
are officially approved for use against SARS-CoV-2(146). 
   
During this study we assessed the antiviral activity of four peptides: DJK-5, IDR-1018, D3006 
and D3007.  Previous studies have found that both DJK-5 and IDR-1018 are both antimicrobial 
and antibiofilm (147).  In addition to its antibiofilm activity IDR-1018 shares synergy to 
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multiple antibiotics and has been studied to see if any variation in its structure confers increased 
antimicrobial activity (102, 148).  We also evaluated the antiviral activity of 14 peptoids: TM1, 
TM2, TM4, TM5, TM6, TM8, TM9, TM12, TM14, TM15, TM18, and TM19, using LL-37 
and its scrambled version (sLL-37) as controls.  Previous research has found that LL-37 has 
anti-influenza activity through both direct viral inhibition as well as indirectly through 
modulation of the immune response (149).  The remaining TM-peptoids are all variations of 
the TM1 peptoid to assess whether modifications will cause antiviral characteristics in the 
peptoids.  
 
1.4. Aims and Hypothesis 
1.4.1  Lack of treatments 
Annual vaccines to prevent infection with IAV are currently the most effective preventative 
measure.  However, their accessibility, cost, and frequency mean that many people are not 
receiving their yearly vaccination.  Additionally, IAV is becoming resistant to the current 
antivirals being used to treat serious cases.  Although to some it may seem as if we are in 
control of seasonal influenza, it still takes many lives each year.  Moreover,  one antigenic shift 
may quickly give rise to the next disastrous pandemic.  Many treatments and vaccines for 
SARS-CoV-2 are currently undergoing stages of drug development, and are being pushed 
through at an unprecedented rate.  However, as this is still a quickly developing field any 
understanding into potential anti-SARS-CoV-2 treatments and preventatives is of utmost 
importance. 
1.4.2  Future directions 
Viral drug discovery is in constant demand with the continued arms race between humans and 
microorganisms.  For every leap in the direction of treating IAV and SAR-CoV-2, these viruses 
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have, and for the foreseeable future will be just one step behind, repeatedly leaving us without 
the means to protect ourselves from them.  The need to discover new antivirals with unique 
targets and to anticipate the next biological leap of IAV and SARS-CoV-2, is essential research. 
1.4.3 Aims  
The aims of this project were to assess the antiviral capabilities and clinical potential of various 
peptides and peptoids against Influenza A Virus and SARS-CoV-2 through the following: 
(i) Determine the cytotoxicity (CC50) of the antimicrobial peptides and peptoids in this 
project in both MDCK and Vero cell lines  
(ii) Evaluate the antiviral activity of these peptides and peptoids against both IAV and 
SARS-CoV-2 through determining EC50 values 
(iii) Determine the selectivity index (SI) of the antimicrobial peptides and peptoids 
against both IAV and SARS-CoV-2  
(iv) Investigate the mechanism of action of peptides and peptoids with clinical potential 
through time-of-drug addition assays 
(v) Determine the viral target of peptides and peptoids with clinical potential through 
selection of resistant viral variants 
1.4.4 Hypothesis 
We hypothesise that at least one of the different antimicrobial peptides/peptoids used in this 
project will be successful in the inhibition of replication of one of the tested viruses (IAV and 
SARS-CoV-2) with negligible cellular toxicity.  We also predict that the mechanism of action 
will be at the viral attachment or entry stage of the lifecycle and that the viral target will 
complement this by  being  one of the viral or cellular surface proteins. 
2. Materials and Methods 
As described above, in this study we aimed to characterize the antiviral activity of a series of 
antimicrobial peptides or peptoids.  Figure 5 describes the overall methodology used to 
evaluate these novel, potential antiviral agents.  
 
Figure 5 Overview of Methodology Student original created on Biorender.com
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2.1 Drugs 
2.1.1 Peptides  
Four peptides were provided by Dr. Daniel Pletzer (Department of Microbiology and 
Immunology, University of Otago, New Zealand).  These were:  DJK-5, IDR-1018, D3006, 
and D3007.  Peptides were received in powder form ranging from 6.3 to 9.1 mg before being 
diluted with phosphate buffered saline (PBS pH 7.3±0.2 by Oxoid Dulbecco A) to 10 mg/mL 
and stored at -20°C in 200 µL aliquots.  When needed for use, peptides were thawed and diluted 
to the required concentration with either cDMEM or infection medium warmed to 37°C.  
 
2.1.2.Peptoids 
Fourteen peptoids were provided by Associate Professor Annelise Barron (Department of 
Bioengineering, Stanford University, USA). These were TM1, TM2, TM4, TM5, TM6, TM8, 
TM9, TM12, TM14, TM15, TM18, TM19, LL-37 and LL-37 Scrambled.  These peptoids, 
received in powder form ranging from 1 to 10 mg and were diluted with PBS (pH 7.3± 0.2) to 
1 mg/mL and stored at -80°C in 200 µL aliquots.   
 
2.2 Cell Lines  
2.2.1 Madin-Darby Canine Kidney Cell Line 
Madin-Darby Canine Kidney (MDCK) cells derived from adult Canis familiaris were used as 
a model of mammalian epithelial cells for the infection of influenza A virus (IAV).  MDCK 
cells (NBL-2;ATCC® CCL-34) were passaged in complete Dulbecco modified Eagle medium 
(cDMEM) (Table 1) at 70% confluency and kept at 37°C, 5% CO2.  For passaging, 1×trypsin 
was added to the flask of cells and incubated at 37°C, 5% CO2  for 5-10 minutes, until cells 
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were no longer adherent.  Next, cDMEM was added to inhibit further trypsinisation, and the 
cells were gently mixed via pipetting. The cells were subsequently placed in a Beckman 
Coulter Allegra X-22 centrifuge at 277 ×g  for 5 minutes.  The supernatant was removed, and 
the cell pellet was resuspended in 5 mL of cDMEM.  Cell density was calculated through 
hemocytometer cell counting after staining cells with trypan blue exclusion (20 µL trypan blue, 
20 µL cell suspension).  Cells were then either placed back into a flask at a 1 in 10 dilution or 
placed into 96 well plates at a density of 103 cells per well. 
 
2.2.2 Elvira® Flu A-Luc Cell Line 
The Influenza reporter cell line Elvira® Flu A-Luc (obtained from Quidel Inc, San Diego, CA) 
was used for the detection of Influenza A Virus (150).  Elvira® Flu A-Luc cell lines contain a 
virus inducible reporter gene segment (VIRGS), which encodes a luciferase protein detectible 
through luminescence screening.  When infected with influenza A virus, this protein is 
expressed allowing a quantifiable rate of infection.  Elvira® Flu A-Luc cells were passaged 
and stored using the same protocol as described for MDCK cell lines.  Before being added to 
96 well plates,  the following fibronectin protocol was carried out to ensure Elvira cells adhered 
sufficiently to the plates.  Human plasma fibronectin (Gibco #33016-015) was diluted to a 
coating concentration of 1-5 µg/cm2 with molecular grade water.  30 µL of the solution was 
added to each well of a Corning Costar 96 well white assay plate and air dried in a biological 
safety cabinet for at least 45 minutes and then left covered at room temperature (RT) overnight.  
From here, Elvira cells were added and experiments were carried out as previously described 
with the MDCK cell line.   
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2.2.3 African Green Monkey Kidney (Vero) Cell Line 
African Green Monkey Kidney cells (ATCC® CCL-81™) were used for viral propagation of 
SARS-CoV-2.  They were maintained and passaged in conditions and media identical to that 
previously described for the MDCK cells with the exception of a seeding density of 2x104 cells 
per well in a 96 well plate.  
 
2.3 Viruses 
The laboratory adapted IAV strain A/Mallard/Alberta/287/2012 (H1N1) was used to infect 
MDCK or ELVIRA cells.  This virus was kept at -80°C until use in assays or propagation.  
Virus was propagated through inoculation of MDCK cells in infection media containing 0.5% 
BSA and 0.1% TPCK.  Three to 5 days after inoculation (dependent upon levels of CPE),  
tissue culture infectivity dose (TCID50) was determined through the Reed & Muench method 
(151).  Once substantial stocks were produced virus was frozen down.  For use in assays IAV 
was thawed on ice and diluted to the appropriate concentration dependent on TCID50 values 
and multiplicity of infection (MOI) required.   
For assays investigating potential anti-SARS-CoV-2 peptides and peptoids the recently 
isolated SARS-CoV-2/Dunedin/1/2020 was used.  All protocols involving SARS-CoV-2 were 
carried out in the Physical Containment 3 laboratory (PC3) by Dr. Rhodri Harfoot. 
 
2.4 Cellular Toxicity Assays  
2.4.1 XTT assay 
Cell Protection assays (XTT) were performed to quantify cellular proliferation and viability of 
MDCK and Vero cell lines that had been treated with the antimicrobial peptides and peptoids.  
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Briefly, 103 cells per well were added to Nonclon Delta Surface 96 well plates 
(ThermoScientific) and grown to 70% confluency.  Peptide and peptoid samples were then 
added in triplicate at 50 µg/ml and a two-fold serial dilution was performed down the plate.  
Cell only controls were used as a marker for 100% cell proliferation and viability.  5% DMSO 
controls were used as a marker for 0% cell viability.  Plates were incubated for 48 hours (hrs) 
at 37°C, 5% CO2.  The XTT labelling mixture was prepared using the Cell Proliferation Kit II 
(XTT; Roche  #11465015001) labelling reagent and electron-coupling reagent at a 5000:1 
ratio.  Supernatant was removed and cells were carefully washed with PBS as to not disturb 
the cell monolayer.  100 µL of PBS was added to each well followed by 50 µL of the XTT 
labelling mixture and incubated at 37°C, 5% CO2 for 4 hrs.  A reagent only control was added 
at this point to account for background absorbance which may occur at the readout stage.  
Absorbances were then measured at 540 nm via a Multiskan FC plate reader 
(ThermoScientific) with reference wavelength of 690 nm was used as a control.  Favipiravir 
was used as a  drug control, known to not affect cell viability.  
 
2.4.2 Neutral Red Assay 
Neutral Red Assays for assessing cellular viability and proliferation were carried out to validate 
the results of the XTT assay.  The same controls were established for this assay including cell 
only, 5% DMSO, and reagent only control.  Cells and potential antivirals were prepared as 
previously described, for the XTT assay and incubated for 48 hrs.  Following incubation with 
the potential antivirals, cell media was removed and PBS was used to wash the cells.  150 µL 
of Neutral Red staining solution was added and cells were incubated for 2 hours at 37°C, 5% 
CO2.  Following this incubation, the Neutral Red staining solution was removed and the cells 
were gently washed with PBS.  Cells were allowed to airdry before 150 µL of solubilising 
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solution was added and plates were placed on a shaker for 20 minutes at room temperature 
(RT). Absorbances were then measured at 540nm via a Multiskan FC plate reader 
(ThermoScientific) with a reference wavelength of 690nm.  
 
2.5 Antiviral Activity Assays  
2.5.1 Tissue Culture Infectious Dose 50 (TCID50) 
The TCID50 experiment is performed with the purpose of titrating the infectious dose of virus 
in various cell cultures such as Elvira cell lines for IAV or Vero cell lines for SARS-CoV-2.  
Briefly, virus was thawed on ice while a confluent 96-well plate of cells was washed with PBS.  
Following the wash step, 90 µL of infection medium was added to all wells in the plate before 
10 µL of virus was added to the first column.  The first column was mixed by gently pipetting 
to not disturb the cell monolayer and a ten-fold serial dilution was performed.  Inoculated cells 
were incubated for 1 hour (hr) at 37°C, 5% CO2 before the inoculum was taken out and replaced 
with 200 µL of infection medium and incubated for 3 days at 37°C, 5% CO2.  After 3 days, 
cytopathic effect (CPE) was assessed in each well with the last column showing CPE 
considered the end point.  TCID50 calculation templates from Reed and Muench were used to 
determine the viral titre from the end point (151). 
 
2.5.2 Elvira Luciferase Assay 
The Elvira Luciferase assay was performed with the Promega Luciferase Assay kit to 
determine the level of influenza virus proliferation through the measurement of luciferase 
expression.  Fibronectin coated, white, clear bottom 96 well cell culture plates with 103 Elvira 
Flu-A-Luc cells per well were incubated overnight before potential antivirals were prepared 
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and added as previously described.  Following a 2 hr incubation with the peptides and peptoids, 
IAV was added at an MOI of 0.01 IU/ml.  Positive controls containing only Elvira cells were 
included to show the highest influenza A virus proliferation rate and a negative control where 
no influenza A virus was added showing the lowest readout.  After incubation for 24 hrs at 
37°C, 5% CO2, the supernatant was removed and the cells were washed with PBS.  Promega 
Luciferase Assay Kit Lysis Reagent was prepared to a 1 X concentration and 20 µL was added 
to each well.  A control well containing only lysis reagent was added to account for background 
luminescence which may occur during the readout.  Plates were then placed through one freeze-
thaw cycle (frozen at -80°C and thawed at RT) before 100 µL of Luciferase Assay Reagent 
was added.  Plates were put into a Varioskan plate reader to follow a luminescence protocol 
with relative light units as the readout. 
 
2.5.3 Virus Yield Assay  
A 70% confluent 96 well plate of MDCK cells was prepared before 50 µg/ml of the peptides 
and peptoids were added in triplicates.  After incubation overnight at 37°C, 5% CO2, IAV was 
added at an MOI of 0.01 IU/ml and incubated at 37°C, 5% CO2.  At the 24, 48, and 72 hr 
timepoint a 50 µL sample of supernatant was taken from each well and placed into a 70% 
confluent 96 well plate of Elvira cells and incubated overnight at 37°C, 5% CO2.  After 
incubation, supernatant was removed and cells were washed with PBS before they underwent 
the same protocol as in the Elvira Luciferase assay.  In brief, 20 µL of Promega Luciferase 
Assay Kit Lysis Reagent was added to each well before the cells were put through one freeze-
thaw cycle and 100 µL of Luciferase Assay Reagent was added and plates were read on the 
Verioskan plate reader.  As with the  Elvira Luciferase assay a cells only control and an 
untreated infected cells control were included to show no influenza A virus infection and 
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complete influenza A virus infection.  Additionally, a reagent only control was included to 
account for background reading on the plate scanner. 
 
2.5.4 SARS-CoV-2 Antiviral Assay: CPE and RT-qPCR 
As previously described, 20,000 Vero cells per well were added to 96-well plates and incubated 
overnight at 37°C, 5% CO2.  Once at 70% confluency, potential antivirals were prepared and 
added to plates in a two-fold serial dilution, in biological triplicate.  The cells were incubated 
with the peptides, peptoids and drug controls for 2 hours before being taken to the PC3 
laboratory.  SARS-CoV-2/Dunedin/1/2020 was added to all wells (MOI of 0.01 IU/ml) 
excluding the cells only control and was incubated at 37°C, 5% CO2 for 1 hour.  After 
incubation, the inoculum was removed and the cells were washed with PBS before the potential 
antivirals were added back in with cDMEM.  Plates were then incubated for 3 days at 37°C, 
5% CO2, and CPE was recorded.  Following this, RT-qPCR was carried out to detect levels of 
SARS-CoV-2 using methods adapted from the Drosten group (152).  In brief, a 10 µL reaction 
was run which included inactivated cell supernatant (1.5 µL), forward primer (400 mM; 
ACAGGTACGTTAATAGTTAATAGCGT), reverse primer (400mM; 
ATATTGCAGCAGTACGCACACA) and a SARS-CoV-2 E-gene probe (200 mM; FAM-
ACACTAGCCATCCTTACTGCGCTTCG- BHQ) as well as the mastermix from Quanta 
qScriptTM XLT One-Step RT qPCR Toughmix (LOW ROX) (Quanta Biosciences). The 
parameters for this experiment were as follows: reverse transcription at 50°C for 10 minutes, 
Taq activation at 95°C for 3 minutes, followed by 45 cycles of 95°C, 5 seconds for 
denaturation, 58°C, 7s for annealing, and finally 60°C, 23s for extension.  The cycle threshold 
(Ct value) was produced for each sample which was compared against the standard curve to 
determine levels of SARS-CoV-2 E-gene present.  Standard curves were generated using 
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synthetic SARS-CoV-2 E-gene RNA in a 10 fold dilution from 1.5x108 to 1.5x102 copies/rxn 
and each sample was run in technical duplicates.   
 
2.6 Statistics 
For cytotoxicity data presented on a bar graph, an ordinary one-way ANOVA with  Dunnett’s 
multiple comparisons test was carried out with samples compared to the cells only control.  For 
antiviral data presented in a bar graph, an ordinary one-way ANOVA was performed with 
samples compared to the infected cells control, as well as a Dunnett’s multiple comparisons 
test.  For data presented on a log scale line graph, data was pruned, normalized, transformed to 
log scale and finally fitted to a non-linear regression curve.  All statistics was performed on 













3.1 Cytotoxicity  
The cytotoxicity of peptides and peptoids was assessed through cell viability (XTT) and 
proliferation assays (Neutral Red staining).  Using a single concentration of 50 µg/ml, we 
observed that none of the peptides showed statistically significant cytotoxicity with either the 
XTT or Neutral Red assays (Figure 6A). Meanwhile, peptoid samples TM1, TM4, TM6, TM8, 
TM9, TM18 and TM19 caused statistically significant (P < 0.0001, 95% CI) cytotoxicity in the 
XTT assay, with similar results in the Neutral red test (Figure 6B, Figure6C).  TM4 still showed 
statistically significant cytotoxicity but with a lower P value (p = 0.0332, 95% CI).  On the 
other hand, neither the TM6 nor the TM8 peptoids showed a statistically significant decrease 






























Figure 6 Cytotoxicity of peptides (A) and peptoids (B, C) measured through cell viability (%).  
Cell viability (%) (Mean + SD) assessed through comparison to 100% viable cells only control via 
the XTT cell viability and proliferation assay via Neutral Red cell viability.  XTT assays were 
performed on Vero cell line groups treated with 50 µg/ml of peptide (A) or peptoid (B) while Neutral 
Red assays were performed on MDCK cell line groups treated with 50 µg/ml of peptide (A) or 
peptoids (B, C). Peptoid results for XTT (B) and Neutral red (C) are shown separately to visualize 
significance. Favipiravir acted as a known drug control which does not affect cell viability at 50 
µg/ml.  All samples were performed in triplicate.  Data was retrieved through reading optical density 
of samples at 570nm and normalized through the removal of reagent only at 570nm and background 
reading at 690nm.  Ordinary one-way ANOVA with Dunnett’s multiple comparisons test against 
cells only control was performed for statistical significance.  None of the peptides showed 
statistically significant cytotoxicity while peptoids samples caused cytotoxicity at 50 µg/ml with 
*P<0.0332 and ****P<0.0001 (Appendix 6). 
 34 
Following the initial test with a high concentration of the peptides and peptoids (50 µg/ml), we 
assessed their cytotoxicity at increasing concentrations using the same methods, to determine 
50% cytotoxic concentration (CC50) values.  A two-fold serial dilution from 0 µg/ml to 50 
µg/ml of peptides and peptoids was carried out and added to each sample in triplicate.  None 
of the peptides appear to cause cytotoxicity at any concentrations (CC50 values >50 µg/ml), 
(Figure 7A)(Figure 7C)(Appendix 2)(Appendix 3).  Additionally, peptoids which showed no 
statistically significant cytotoxicity (i.e., TM2, TM5, TM12, TM14, and TM15, as well as the 
controls LL-37 and  sLL-37), were also classified as having  CC50 values  >50 µg/ml (Figure 
7B)(Figure 7D).  For peptoids samples which caused statistically significant cytotoxicity at 50 
µg/ml we were able to calculate a CC50 value.  TM1 results showed a CC50 of 29 µg/ml for 
MDCK cells and 28 µg/ml for Vero cells.  TM4 showed a CC50 of 29 µg/ml for MDCK cells 
and 34 µg/ml for Vero cells.  TM6 showed a CC50 of 50 µg/ml for both MDCK and Vero cells.  
TM8 showed a CC50 of 22 µg/ml for MDCK cells and 25 µg/ml for Vero cells.  TM9 showed 
a CC50 of 20 µg/ml for MDCK cells and 28 µg/ml for Vero cells.  TM18 showed a CC50 of 35 
µg/ml for MDCK cells and 31 µg/ml for Vero cells.  TM19 showed a CC50 of 28 µg/ml for 
MDCK cells and 27 µg/ml for Vero cells (Appendix 4)(Appendix5).  The Favipiravir control 
















Figure 7 Cytotoxicity of Peptides (A, C) and Peptoids (B, D) at increasing concentration (µg/ml), measured through 
cell viability (%). 
Cell viability (%) assessed through the XTT cell viability and proliferation assay and the Neutral Red cell viability 
staining through comparison to 100% viable cells only control.  XTT assays were performed on Vero cell line 
groups treated with a two-fold serial dilution (0.39 µg/ml to 50 µg/ml) of peptide (A) or peptoid (B).  Neutral Red 
assays were performed on MDCK cell line groups treated with a two-fold serial dilution (0.39 µg/ml to 50 µg/ml) 
of peptide (C) or peptoid (D).  Favipiravir acted as a known drug control which does not affect cell viability at 50 
µM.  All samples were performed in triplicate.  Data was retrieved through reading optical density of samples at 
570nm and normalized through the removal of reagent only at 570nm and background reading at 690nm.  None of 
the peptide samples appear to cause cytotoxicity at any concentration.  Peptoids samples which caused statistically 
significant cytotoxicity at 50 µg/ml (TM1/TM4/TM8/TM9/TM18/TM19) begin to show cytotoxic effects at 20 µg/ml. 
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3.2 Anti-Influenza A Virus Activity 
In-vitro anti-IAV activity of the peptides and peptoids was first assessed through the Elvira 
Luciferase Assay using a single concentration (50 µg/ml) of the different peptides and peptoids.  
All peptides caused statistically significant (P 0.0002, 95% CI) reduction in viral replication at 
50 µg/ml (Figure 8A), as did all peptoid (P <0.0001, 95% CI) samples (Figure 8B).   
 
A Virus Yield Reduction Assay was performed with the same parameters as the Elvira 
Luciferase assay as a secondary test to validate these results.  From this experiment, only 
peptides IDR-1018, D3006, and D3007 showed statistically significant (P 0.0332, 95% CI) 
reduction in viral replication at 50 µg/ml (Figure 8C).  This test did not show DJK-5 as causing 
any statistically significant reduction in IAV replication.  Peptoid results from the virus yield 
reduction assay showed that TM1, TM4, TM6, TM8, TM9, TM18, TM19, sLL-37 caused a 
statistically significant (P 0.0021, 95% CI) reduction in IAV replication at 50 µg/ml, while 
TM2 and LL-37 also showed significant reduction but with a lower P value (p = 0.0332, 95% 
CI)(Figure 8D).  The remaining peptoids: TM5, TM12, TM14, and TM15, failed to show 





Figure 8 Reduction of Influenza A Virus replication following treatment with 50 µg/ml peptides and peptoids.   
Reduction (Mean + SD) of viral replication was assessed through the use of the luciferase reporter gene in the Elvira 
Flu-A Luc cell line (A, B).  Elvira cells treated with 50 µg/ml of peptide or peptoid were inoculated with influenza A 
virus (IAV) triggering luciferase gene expression which was assessed through luminescence screening.  Reduction 
was validated through a virus yield reduction assay (C, D).   Data was received in relative light units and normalized 
through the removal of reagent only background reading.  Samples were performed in triplicate and compared 
against a cells only control and a virus infected cells control.  Data is plotted in log scale to show suggestive reduction 
in replication.  Data was analysed through an ordinary one-way ANOVA with Dunnett’s multiple comparisons test 
against virus infected cells control.  Significance is shown with asterixis and peptoids known to be cytotoxic have 
been marked with a red “T”.  All peptide samples caused statistically significant reduction in viral replication at 50 
µg/ml with a ***P <0.0002.  Multiple peptoids samples caused statistically significant reduction in viral replication 
at 50 µg/ml with a ****P<0.0001 (Appendix 7). 
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Further Elvira Luciferase assays were completed at a two-fold dilution (0 µg/ml to 50 µg/ml) 
of peptides (Figure 9A) and peptoids (Figure 9B) to determine their 50% effective 
concentration (EC50) values reducing IAV replication.  The EC50 values were determined for a 
IDR-1018 (5.7 µg/ml), D3006 (49 µg/ml) and D3007 (28 µg/ml) (Appendix 2).  We were not 
able to determine an EC50 value for DJK-5 as it did not significantly decrease IAV replication.  
EC50 values were not determined for TM1, TM4, TM8, TM9, and TM19 due to their 
cytotoxicity.  Furthermore, EC50 values were not determined for TM5, TM12 or TM15 due to 
their inability to significantly reduce IAV replication.  Therefore, EC50 values were determined 
for TM2 (28 µg/ml), TM14 (11 µg/ml) and the control LL-37 (10.9 µg/ml)(Appendix 5).  In 
addition, the EC50 values for TM6 (5.9 µg/ml) and TM18 (18 µg/ml) were determined 
regardless of their statistically significant (P <0.0001, 95% CI) cytotoxicity, as the results from 
those assays were varied.  The negative control scrambled LL-37 was not able to significantly 
reduced IAV replication while the positive control Favipiravir had an EC50 of 0.98 µg/ml.   
Finally, we used the CC50 and EC50 values to determine the selectivity index (SI) of the 
peptides, peptoids.  SI values were able to be calculated for IDR-1018, D3006, D3007, TM2, 
TM6, TM14, TM18, LL-37, and Favipiravir (Appendix 2-5).  Notably, peptide IDR-1018 and 
peptoid TM14, as well as LL-37 all showed low levels of cytotoxicity and high anti-IAV 




3.3 Anti-Severe Acute Respiratory Syndrome Coronavirus Activity 
Anti-SARS-CoV-2 activity of peptides and peptoids was assessed by quantifying the level of 
the SARS-CoV-2 E gene (viral replication) using RT-qPCR.  Presence and levels of the SARS-
CoV-2 E gene was determined through standardizing against the increased presence of 
synthetic E gene.  Peptide or peptoid samples were tested to determine their anti-SARS-CoV-
2 activity at a single concentration 50 µg/ml, using Remdesivir (50 µM) as a control to model 
reduction in viral replication.  Here we observed that all peptides caused statistically significant 
(P 0.0021, 95% CI) reductions in SARS-CoV-2 replication (Figure 10A)(Appendix 3).  
Additionally, all peptoids tested also caused statistically significant (P <0.0001, 95% CI) 
reductions in SARS-CoV-2 replication (Figure 10B), including the scrambled LL-37 (P 
0.0002, 95% CI)(Appendix 5).  
 
Figure 9 Reduction of Influenza A Virus replication following treatment with increasing concentrations (µg/ml) of 
peptides and peptoids. 
Reduction of viral replication was assessed through the use of the luciferase reporter gene in the Elvira Flu-A Luc cell 
line.  Elvira cells groups were treated with a two-fold serial dilution (0.39 µg/ml to 50 µg/ml) of peptide (A) or peptoid 
(B). Cells were then inoculated with IAV triggering luciferase gene expression which was assessed through 
luminescence screening.  Data was received in relative light units and normalized through the removal of reagent only 
background reading.  Samples were performed in triplicate and are compared against a cells only and a virus infected 
cells controls.  Data is plotted in log scale to show suggestive reduction in replication.  All samples tested caused 




Based on these first results, we assessed for anti-SARS-CoV-2 activity at increasing 
concentrations from 0 µg/ml to 50 µg/ml to determine the EC50 of each peptide, peptoid.  Of 
those samples which do not cause cytotoxicity, the peptide samples showed EC50 values of 41 
µg/ml (DJK-5), 28 µg/ml (IDR-1018), 11µg/ml (D3006) and 32 µg/ml (D3007), (P 0.0021, 
95% CI) (Figure 11A)(Appendix 3).  Meanwhile, results for the peptoid samples showed EC50 
values of 4.2 µg/ml (TM2), 4.6 µg/ml (TM5), 3.2 µg/ml (TM6), 9.5 µg/ml (TM12), 2.8 µg/ml 
(TM14), 2.4 µg/ml (TM15), 28 µg/ml (LL-37), and 45 µg/ml (sLL-37)(Figure 11B)(Appendix 
5). 
 
Figure 10 Reduction of Severe Acute Respiratory Syndrome Coronavirus 2 replication following treatment with 50 
µg/ml peptides and peptoids.   
Reduction (Mean + SD) of viral replication assessed through RT-qPCR of the SARS-CoV-2 E gene.  Vero cells 
were treated with 50 µg/ml of peptide (A) or peptoid (B) and inoculated with SARS-CoV-2 before a 3 day 
incubation.  1.5 µl of inactivated samples were run in a 10 µL RT qPCR reaction with primers (400 mM), a probe 
(200 mM) and Quanta qScript Toughmix.  All samples were performed in biological triplicate and technical 
duplicates.  Experiment includes a cells only control and virus infected cells control as well as Remdesivir to model 
reduction in viral replication.  Data presented in RNA copies per PCR run in log scale to show suggestive reduction 
in replication.  Data was analysed with an ordinary one-way ANOVA with Dunnett’s multiple comparisons test 
against virus infected cells control.  All peptide samples caused statistically significant reduction in SARS-CoV-2 
replication at 50 µg/ml (**P<0.0021).  Excluding peptoids known to be cytotoxic, all samples caused statistically 





From these results we were able to calculate the selectivity index for the peptides: DJK-5 (1.2), 
IDR-1018 (1.8), D3006 (4.5), D3007 (1.6)(Appendix 3).  As well as for the peptoids: TM1 
(23), TM2 (11.9), TM4 (35.8), TM5 (10.8), TM6 (15.6), TM8 (78.1), TM9 (2.8), TM12 (5.3), 
TM14 (17.9), TM15 (20.8), TM18 (4.2), TM19 (19.3), LL-37 (1.8) and sLL-37 (1.1)(Appendix 
5).  As comparison, the well-known Remdesivir, with a CC50 >50 and EC50 of 0.85, resulted in 
a SI value of 58.8. 
 
Figure 11 Reduction of Severe Acute Respiratory Syndrome Coronavirus 2 replication following treatment with 
increasing concentration (µg/ml) of peptides and peptoids.   
Reduction of viral replication assessed through RT-qPCR of the SARS-CoV-2 E gene.  Vero cells treated with 
increasing concentrations (0.39 µg/ml to 50 µg.ml) of peptide (A) or peptoid (B) and inoculated with SARS-CoV-
2 before a 3 day incubation.  1.5 µl of inactivated samples were run in a 10 µL RT-qPCR reaction with primers 
(400 mM), a probe (200 mM) and Quanta qScript Toughmix.  To determine RT-qPCR threshold, standard curves 
were generated using synthetic SARs-CoV-2 E-gene RNA in a 10-fold dilution (1.5×108 to 1.5×102).  All samples 
were performed in biological triplicate and technical duplicates.  Experiments included a cells only control and 
virus infected cells control as well as Remdesivir as a control to model reduction in viral replication.  Data is of 
the RNA copies per PCR run in log scale to show suggestive reduction in replication.  All of the peptide and 
peptoid samples to reduced SARS-CoV-2 replication before the final concentration of 50 µg/ml.   
 
 
4. Discussion  
Respiratory viruses continue to pose an important threat to the human population, with 
influenza virus and SARS-CoV-2 being two of the most relevant at present.   In this study, we 
were able to answer three of the research questions we aimed to address with the antimicrobial 
peptides and peptoids: (i) determine their cytotoxicity in both MDCK and Vero cells, (ii) 
evaluate their antiviral activity against both IAV and SARS-CoV-2, and (iii) use this 
information to determine their selectivity indices, deciding if further studies (e.g., preclinical 
and animal model) are warranted to infer their potential use in the clinical setting.   Our results 
show that six of the eighteen peptides and peptoids caused significant cytotoxicity (CC50 >50 
µg/ml).  For the remaining twelve, we were able to evaluate their antiviral activity against IAV 
and SARS-CoV-2, finding that eight and twelve showed some potential as anti-IAV and anti-
SARS-CoV-2 agents, respectively (SI values ranging from 1 to 20.8).  These results support 
our original hypothesis, that some of the antimicrobial peptides and/or peptoids were going to 




The research objective with this portion of experiments was to determine the cytotoxicity 
(CC50) of the peptides and peptoids in both MDCK and Vero cell lines.  We achieved this by 
first assessing the cytotoxic effect at 50 µg/ml. The XTT cell proliferation and viability assay 
was used which is a commonly used method within the field for measuring cell viability in 
multiple cell lines (153-158).  In addition, to validate these results, the neutral red cell viability 
stain was used, which is one of the most used methods within the field (158-163).  Results from 
this showed that none of the peptides caused statistically significant cytotoxicity with either 
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viability assay.   While antimicrobial peptoids TM1, TM4, TM6, TM8, TM9, TM18, TM19 
caused significant cytotoxicity in the neutral red assay, only TM1, TM9, TM18, TM19 caused 
the same result with the XTT.  Interestingly, TM4 showed far less cytotoxic activity in the XTT 
assay compared to the neutral red assay.  In addition, TM6 and TM8 caused significant 
cytotoxicity in the neutral red assay but not in the XTT assay. In contrast, TM2 and TM5 caused 
significant cytotoxicity in the XTT but not in the neutral red assay.  The differences seen 
between the results produced from these two assays could be due to the different ways in which 
the assays work.  The XTT assay measures cell viability through metabolically active cells 
cleaving the tetrazolium salts resulting in a coloured product (158, 164), whereas, the neutral 
red stain assay measures cell viability through the incorporation of the neutral red dye into 
integrally sound lysosomes (158, 163).  Therefore, differences in how these peptides and 
peptoids are affecting the cells could be the reason for the slight differences in cell viability 
results.  
 
Overall, we are confident in the results seen in both the neutral red and XTT assays with both 
cell lines as the Favipiravir control showed no cytotoxicity, as seen in the literature (111, 165, 
166). In addition to this, the LL-37 peptide both intact and scrambled caused no cytotoxicity 
as has been shown in other studies, further validating our results (167-169) . 
 
Following on from the single concentration test, we determined CC50 values through the same 
assays with varying concentrations of antimicrobial peptides and peptoids (i.e., 0.39 µg/ml to 
50 µg/ml).  As expected, the peptides did not cause cytotoxicity at any lower concentrations, 
validating the results of the first experiments.  Our results validate data obtained previously 
where both DJK-5 and IDR-1018 peptides were studied for their antibiofilm activity (170-173).  
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During those studies DJK-5 and IDR-1018 was not found to exhibit any cytotoxic effects on 
the host cells (173).  Currently, the Pletzer Lab (Department of Microbiology and Immunology, 
University of Otago) is carrying out studies which will include cytotoxicity of the other two 
peptides (D3006 and D3007), but have not yet published results.  Therefore, it is promising for 
the future of these peptides that we have shown they do not exhibit significant cytotoxic effects 
on MDCK or Vero cell lines.  In addition to the peptides,  antimicrobial peptoids TM2, TM5, 
TM12, TM14, TM15, LL-37 – as well as the sLL-37 control - were all determined to have 
CC50 values > 50µg/ml as they did not cause significant cytotoxicity at the max concentration 
of 50 µg/ml.  This was expected for LL-37 and scrambled LL-37 and aligns our results with 
the current literature, as LL-37 has previously been investigated as an anti-influenza peptide 
(167-169).  Meanwhile, scrambled LL-37 has been used as a negative control in similar studies 
(167, 174, 175).   
 
It is important to highlight that al the TM-peptoids are variants of the original peptoid TM1 
(H-(NLys-Nspe-Nspe)4-NH2), which has previously been shown to have  antimicrobial effects 
(176-178).  The rest of the peptoids in this study were modified from TM1 to discover if further 
antimicrobial properties could be utilised.  In our study we found the CC50 of TM1 was 
consistent between the two assays however, current literature has deemed TM1 as non-toxic 
whereas we found toxicity at ~29 µg/ml (176).  TM8, TM9 and TM19 all caused enhanced 
cytotoxic effects from the original TM1 while, peptoids TM4 and TM18 showed a reduced 
cytotoxic effect in relation to TM1.  These results may be explained by the modifications made 
to these peptides.  A slight modification to side chain length and residues can significantly alter 
the cytotoxicity and antimicrobial capabilities of peptides and peptoids (179-181). This could 
therefore explain our results. TM6 also showed a reduced cytotoxic effect with a CC50 value 
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of 50 µg/ml in both MDCK and Vero cells which is supported in a previous study assessing 
the anti-tuberculosis capability of TM6 (176) .  
 
From these results, and previous studies, we concluded that none of the peptides were 
exhibiting cytotoxic effects. In addition, we concluded that in our study TM1, TM4, TM8, 
TM9, TM18 and TM19 were exhibiting cytotoxic effects.  Further investigation into the 
cytotoxic effects seen with TM1 will have to be investigated due to the conflict in results seen 
with other literature.  This conclusion left DJK5, 1018, D3006, D3006, TM2, TM5, TM6, 
TM12, TM14, TM15, and LL-37 as the viable peptides and peptoids to be evaluated as 
potential antiviral agents.  
 
4.2 Anti-influenza A virus  
Here we aimed to evaluate the anti-IAV activity of the peptides and peptoids through 
determining EC50 values followed by calculating the SI to determine clinical potential.  Our 
initials test utilised the measurement of viral stimulated luminescence through the Elvira-FluA-
Luc cell line with peptides and peptoids at the single concentration of 50 µg/ml. The method 
of using the enzyme-linked virus inhibitor reporter assay (ELVIRA) to determine antiviral drug 
susceptibilities has been developed for drug susceptibility  herpes simplex virus (182).  Since 
then it was modified for use of drug susceptibility of IAV in 2006, where it was shown to 
produce accurate results of IAV replication (150).  We utilised the ELVIRA Flu-A-luc cell line 
to assess drug susceptibility with luminometric measurements (150).  Results from this showed 
there was a statistically significant reduction in viral replication from treatment with all 
peptides or peptoids.  We attempted to validate these results with a virus yield reduction assay 
which involves the use of both MDCK and Elvira cell lines (183).  Although perhaps not 
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showing the same levels of viral reduction or significance, we still observed that IDR-1018, 
D3006, D3007, TM2 and LL-37 showed significant viral reduction.  We were unable to show 
significant viral reduction for DJK-5, TM5, TM12 or TM15.  A potential reason for this 
discrepancy  in results could be the overall reduction in cell growth seen in the virus yield 
assay.  This can be seen when reviewing RLU measured from the cell only control and the 
infected cell control. Our experiment measuring viral reduction directly in Elvira cells shows 
IAV infected cells left untreated had an output of 107 RLUs, whereas this same control in the 
virus yield assay only had an output of <105 RLUs.  This is validated with our cells only control 
which had an output of >104 in the assay measuring reduction directly in Elvira cell and 102 
RLUs in the virus yield assay.  This overall lowered cell growth (or possibly increased death) 
could have affected our results whereby showing that the peptides and peptoids had less anti-
influenza activity than they may actually have.  
 
Following the single concentration tests, we assessed the activity of those peptides and peptoids 
which showed statistically significant viral reduction at a range of concentrations (0 µg/ml to 
50 µg/ml) to determine the EC50 values.  DJK-5, TM5, TM12 and TM15 were not included in 
this experiment as they failed to show significant viral reduction at 50 µg/ml.  Additionally, 
TM1, TM4, TM8, TM9 and TM19 were excluded due to their high cytotoxicity.  This shows 
they are unlikely to be suitable for clinical use unless modified to reduce their cytotoxic effects, 
as has been trialled for one of the peptide samples (170).  EC50 and SI values were determined 
for all remaining peptides and peptoids with the most interesting results obtained with peptide 
IDR-1018 and peptoid TM6, which had the largest SI values (8.8. and 8.5, respectively).  As 
described above, SI is a ratio calculated from the 50% cytotoxic concentration (CC50) and the 
50% effective concentration (EC50) of the peptide or peptoid (184).  The larger the ratio, the 
larger the therapeutic window is for clinical treatment, because of this, we use the SI as an 
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indicator for the likelihood of a peptide or peptoid being clinically useful (185).  Peptide IDR-
1018 (8.8) and peptoid TM6 (8.5) showed the largest SI values for IAV; however, when 
compared to the known anti-IAV control drug (Favipiravir) with an SI of 51, they are still 
relatively small values.  Further work is needed to re-design and improve these antimicrobial 
peptide, peptoid in order to evaluate the potential use as effective drugs at treating IAV. 
However, as discussed previously, the drug development process is long and arduous and with 
refinements and additives, they hold promise for future anti-IAV treatments (87, 88, 170).  
 
Overall, we are confident in the results observed and interpretations made from the single and 
serial concentration experiments as our positive control was able to significantly reduce viral 
replication with an EC50 of 0.98 µM with a calculate SI of 51.  This is consistent with previous 
studies which show Favipiravir to have EC50 values ranging from 0.15 to 2.4 µM (111, 186, 
187). Additionally, LL-37, a peptoid previously shown to have anti-IAV activity was 
determined to have an EC50 value of 10.9 µg/ml and an SI of 4.6 in Elvira cells (149, 167-169).  
This aligns with previous studies, which showed LL-37 having EC50 values between 2 to 20 
µg/ml for influenza A virus (168, 188).  Previous research also showed that when scrambled, 
LL-37 lost anti-influenza A virus activity (167-169).  Our research aligns with these findings 
as we were unable to find significant reduction in IAV replication following treatment with 
sLL-37. 
 
4.3 Anti-SARS-CoV-2  
With this portion of the study we aimed to discover anti-SARS-CoV-2 activity of the peptides 
and peptoids through determining EC50 values, followed by calculating the SI to determine 
clinical potential.  Our initial test utilised RT-qPCR targeting the essential SARS-CoV-2 E-
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gene to detect reduction in viral replication at the single concentration of 50 µg/ml.  RT-qPCR 
has been used extensively over the last year to assess the presence or absence and quantity of 
SARS-CoV-2 as well as detect anti-SARS-CoV-2 activity (189-193). As it has been shown to 
be an accurate quantitative technique to assess virus amount in a sample .  Our RT-qPCR results 
showed there was a statistically significant reduction in viral load from treatment with any of 
the tested peptides (P 0.0021, 95% CI) or peptoids (P <0.0001, P 0.0002, 95% CI).  Of 
important note are D3006, TM14, TM15 which caused reduction in the viral load below the 
positive threshold of the RT-qPCR, as is determined with a synthetic E-gene RNA dilution 
series. This means that the viral load was low enough to be considered a negative sample for 
SARS-CoV-2 replication.  This is the same effect we observed when we assessed the 
Remdesivir positive control which aligns with our earlier results and is also is supported by 
previous research (194). 
 
Following the single concentration tests, we determined EC50 values for all peptides and 
peptoids through addition of a range of concentrations (0 µg/ml to 50 µg/ml) in Vero cells 
against SARS-CoV-2.  With these results we were able to determine the SI for all peptides and 
peptoids.  As previously discussed, the SI or therapeutic index is used as an indication of 
whether the drug may be useful in a clinical setting (185).  As an example of this, multiple 
studies claim Remdesivir, which was approved for emergency SARS-CoV-2 treatment, has an 
SI >100(195).  While in contrast anti-IAV drug Favipiravir has an SI >6.46 against SARS-
CoV-2 (195).  Both are considered to show inhibitory effects on SARS-CoV-2 replication, 
however Remdesivir is far superior at inhibiting replication (195).  
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When comparing our most notable results from peptoids TM6, TM14 and TM15, we observe 
that they possess SI values between those of Remdesivir and Favipiravir.  TM6, TM14 and 
TM15 have SI values of 15.6, 17.9 and 20.8 respectively, as well as CC50 values ≤ 50 µg/ml.  
As this is a preliminary study of the potential anti-SARS-CoV-2 activity of these peptides and 
peptoids, we are hopeful that further testing will validate and expand our results, thus offering 
potential drug candidates for SARS-CoV-2.  In addition to these three promising peptoids, we 
also observed peptoids TM4 (SI = 35.5)  and TM8 (SI = 78.1) had a much larger SI values, 
however, both caused statistically significant cytotoxicity with CC50 values of 34 µg/ml and 25 
µg/ml respectively.  Regardless, TM4 and TM8 still hold promise as anti-SARS-CoV-2 drug 
candidates if they are able to be modified to lower their cytotoxic effect.  
 
Overall, we are confident in the results observed and interpretations made from the single and 
serial concentration experiments, as our positive control, Remdesivir, was able to significantly 
reduce viral replication with an EC50 of 0.85 µM and calculated SI of 58.8.  This aligns with 
the results of previous studies which showed the EC50 of Remdesivir to be between 0.14 µM 
and 1.76 µM (196-199).  Although these results look promising only one type of assay has 
been used to assay the potential antiviral activity of these peptides and peptoids against SARS-
CoV-2.  Given more time we would have liked to validate these results utilising other methods 
such as immunofluorescence and luminescence as well as plaque assays, as seen in 
previousSARS-CoV-2 studies this year (190, 192, 200).   
 
4.4 Limitations and Future Directions 
The conclusions of this study need to be considered with the acknowledgment of some 
limitations.  First of all, this is a preliminary study of the potential antiviral effects of a panel 
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of antimicrobial peptides and peptoids.  Because of this, a very small number of replicates 
(n=3) were included in order to achieve the research aims in a short period of time.  Future 
studies with much larger biological and technical replicates need to be carried out to validate 
our results and prove statistical significance.  In addition to this, the peptides and peptoids 
should be assessed against a range of different cell lines, not just the MDCK and Vero tested 
in this study.  This is essential to validate our results and to ensure no significant cytotoxic 
effects are seen if any of the peptides/peptoids move into clinical research.  The time restraints 
on this study meant that we were only able to fully complete the first three research aims of 
our proposed work.  Because of this, there are ample research opportunities following on from 
our study which will be undertaken in the next few months. First we will address our 4th 
research aim of determining the mechanism of action of antiviral peptides and peptoids through 
time-of-drug addition assays.  This would provide us with insight about what stage in the viral 
life cycle is being targeted by the antiviral.  Ideally the promising antiviral peptides/peptoids 
would then be assessed for activity against a panel of different viruses to determine their 
antiviral specificity to IAV and SARS-CoV-2.  Following on from this, research should look 
at the development of resistance to these antivirals in IAV and SARS-CoV-2, determining 
likely areas for mutations via site directed mutagenesis and sequencing.  Antiviral peptides and 
peptoids which show particular clinical promise should be investigated in animal models.  Our 
laboratory would collaborate with Dr. Eric Arts from the Western University, Ontario, for 
animal model work on anti-SARS-CoV-2 peptides or peptoids.  While collaboration for animal 
work on anti-IAV peptides and peptoids would likely be with Dr. Richard Webby from the St. 
Jude Children’s research hospital. 
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4.6 Concluding Remarks 
The development of new and effective treatments for both SARS-CoV-2 and IAV is imperative 
in the battle against antiviral resistance.  The pandemic causing antigenic shifts in IAV as well 
as the current SARS-CoV-2 pandemic has enlightened many to the essential work of drug 
discovery.  With this study we set out to characterise the potential antiviral capabilities of a 
panel of peptides and peptoids.  We succeeded in the discovery of multiple potential anti-IAV 
and anti-SARS-CoV-2 drug candidates and will be continuing our work to validate these results 
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Table 1 Media and Reagents 
Material Contents 
Complete Dulbeco modified Eagle medium 
(cDMEM) 
Dulbeco modified Eagle medium  
10% Fetal bovine serum  
1% Penicillin-Streptomycin (100 U/mL) 
Phosphate Buffered Saline 1 tablet Phosphate buffered saline 
(Dulbecco A) pH 7.3±0.2 by Oxoid 
100mL Milli-Q water 
Infection media  Dulbeco modified Eagle medium  
0.5% Bovine serum albinum  
0.1% TPCK  
Neutral Red Staining solution 0.26% Neutral Red Reagent 
99.74% Phosphate buffered saline 
(Dulbecco A) pH 7.3±0.1 by Gibco 
Solubilising Solution 50% Ethanol 
50% Molecular grade water 












 Table 1: In vitro cytotoxicity and anti-Influenza A Virus  activity of peptides 
 Influenza A/Mallard/Alberta/287/2012 (H1N1) 
 *CC50 MDCK (µg/ml) *EC50 ELVIRA (µg/ml) *SI 
DJK-5 >50 nd nd 
IDR-1018 >50 5.7 8.8 
D3006 >50 49 1 
D3007 >50 28 1.8 
 CC50 MDCK (µM) EC50 ELVIRA (µM)  
Favipiravir >50 0.98 51 
Remdesivir nd nd nd 





















 Table 2: In vitro cytotoxicity and anti-Severe Acute Respiratory Syndrome Coronavirus 2 activity of peptides 
 SARS-CoV-2/Dunedin/1/2020 
 CC50 Vero (µg/ml) EC50 Vero (µg/ml) *SI 
DJK-5 >50 41 1.2 
IDR-1018 >50 28 1.8 
D3006 >50 11 4.5 
D3007 >50 32 1.6 
 CC50 Vero (µM) EC50 Vero (µM)  
Favipiravir nd nd nd 
Remdesivir >50 0.85 58.8 





















Table 3: In vitro cytotoxicity and anti-Influenza A Virus activity of peptoids 
 Influenza A/Mallard/Alberta/287/2012 (H1N1) 
 CC50 MDCK (µg/ml) EC50 ELVIRA (µg/ml) SI 
TM1 29 nd nd 
TM2 >50 28 1.8 
TM4 29 nd nd 
TM5 >50 nd nd 
TM6 50 5.9 8.5 
TM8 22 nd nd 
TM9 20 nd nd 
TM12 >50 nd nd 
TM14 >50 11 4.5 
TM15 >50 nd nd 
TM18 35 18 1.9 
TM19 28 nd nd 
LL-37 >50 10.9 4.6 
sLL-37 >50 nd nd 
 CC50 MDCK (µM) EC50 ELVIRA (µM)  
Favipiravir >50 0.98 51 
Remdesivir nd nd nd 
















Table 4: In vitro cytotoxicity and anti-Severe Acute Respiratory Syndrome Coronavirus 2 activity of peptoids 
 SARS-CoV-2/Dunedin/1/2020 
 CC50 Vero (µg/ml) EC50 Vero (µg/ml) SI 
TM1 28 1.2 23 
TM2 50 4.2 11.9 
TM4 34 0.95 35.8 
TM5 >50 4.6 10.8 
TM6 50 3.2 15.6 
TM8 25 0.32 78.1 
TM9 28 10 2.8 
TM12 >50 9.5 5.3 
TM14 >50 2.8 17.9 
TM15 >50 2.4 20.8 
TM18 31 7.3 4.2 
TM19 27 1.4 19.3 
LL-37 >50 28 1.8 
sLL-37 >50 45 1.1 
 CC50 Vero (µM) EC50 Vero (µM)  
Favipiravir nd nd nd 
Remdesivir >50 0.85 58.8 
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 MDCK (XTT) Vero (NR) 
 Significance P value Significance P value 
DJK-5 ns 0.86 ns 0.73 
IDR-1018 ns 0.95 ns 0.27 
D3006 ns 0.99 ns 0.14 
D3007 ns 0.99 ns 0.99 
TM1 **** <0.0001 **** <0.0001 
TM2 ns 0.94 * 0.017 
TM4 **** <0.0001 * 0.04 
TM5 ns 0.49 * 0.014 
TM6 **** <0.0001 ns 0.99 
TM8 **** <0.0001 ns 0.99 
TM9 **** <0.0001 **** <0.0001 
TM12 ns 0.94 ns 0.99 
TM14 ns 0.99 ns 0.98 
TM15 ns 0.99 ns >0.99 
TM18 **** <0.0001 **** <0.0001 
TM19 **** <0.0001 **** <0.0001 
LL-37 ns 0.99 ns 0.99 
SLL-37 ns >099 ns >0.99 
Favipiravir ns 0.99   
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Table 7: Significance of Anti-Influenza A Activity of Peptides and Peptoids 
 IAV 50µg Virus Yield Reduction Assay 
 Significance P value Significance P value 
DJK-5 *** 0.0004 ns 0.18 
IDR-1018 *** 0.0001 * 0.044 
D3006 *** 0.0001 * 0.041 
D3007 *** 0.0001 * 0.0421 
TM1 **** <0.0001 ** 0.0036 
TM2 **** <0.0001 * 0.0262 
TM4 **** <0.0001 ** 0.0027 
TM5 **** <0.0001 ns 0.7143 
TM6 **** <0.0001 ** 0.0069 
TM8 **** <0.0001 ** 0.0062 
TM9 **** <0.0001 ** 0.0024 
TM12 **** <0.0001 ns >0.9999 
TM14 **** <0.0001 ns 0.125 
TM15 **** <0.0001 ns 0.2159 
TM18 **** <0.0001 ** 0.0024 
TM19 **** <0.0001 ** 0.003 
LL-37 **** <0.0001 * 0.0307 
SLL-37 **** <0.0001 ** 0.0072 













 Table 8: Significance of Anti-Severe Acute Respiratory Syndrome Coronavirus Activity of Peptides and Peptoids 
 
50µg Significance P value 
DJK-5 ** 0.0017 
IDR-1018 ** 0.0016 
D3006 ** 0.0016 
D3007 ** 0.0016 
TM2 **** <0.0001 
TM5 **** <0.0001 
TM6 **** <0.0001 
TM12 **** <0.0001 
TM14 **** <0.0001 
TM15 **** <0.0001 
LL-37 **** 0.0001 
SLL-37 *** 0.0003 
Cells only **** <0.0001 
Remdesivir **** <0.0001 
 
